Efficacy of Ezetimibe/Simvastatin 10/20 mg and MK0524A (1-2 g/Day) in Patients With Mixed Hyperlipidemia and Two or More Risk Factors to Cardiovascular Disease.

Trial Profile

Efficacy of Ezetimibe/Simvastatin 10/20 mg and MK0524A (1-2 g/Day) in Patients With Mixed Hyperlipidemia and Two or More Risk Factors to Cardiovascular Disease.

Withdrawn prior to enrolment
Phase of Trial: Phase IV

Latest Information Update: 27 Mar 2015

At a glance

  • Drugs Ezetimibe/simvastatin (Primary) ; Niacin/laropiprant (Primary)
  • Indications Hyperlipoproteinaemia type V
  • Focus Therapeutic Use
  • Most Recent Events

    • 22 Jun 2011 Actual initiation date (Nov 2009) added as reported by ClinicalTrials.gov.
    • 22 Jun 2011 Planned end date changed from 1 May 2009 to 1 Sep 2010 as reported by ClinicalTrials.gov.
    • 22 Jun 2011 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top